Top

Published in:

Open Access 01-12-2020 | Coronavirus | Review

Cardiovascular Implications and Therapeutic Considerations in COVID-19 Infection

Authors: Gregory L. Judson, Benjamin W. Kelemen, Joyce N. Njoroge, Vaikom S. Mahadevan

Published in: Cardiology and Therapy | Issue 2/2020

Abstract

The ongoing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has profoundly impacted all fields of medicine. Infection with SARS-CoV-2 and the resulting coronavirus of 2019 (COVID-19) syndrome has multiorgan effects. The pandemic has united researchers from bench to bedside in attempts to understand the pathophysiology of the disease and define optimal treatment strategies. Cardiovascular disease is highly prevalent and a leading cause of death across gender, race, and ethnic groups. As the pandemic spreads, there is increasing concern about the cardiovascular effects of the viral infection and the interaction of infection with existing cardiovascular disease. Additionally, there are concerns about the cardiac effects of the numerous treatment agents under study. It will be essential for cardiologists to understand the interplay between underlying cardiac comorbidities, acute cardiovascular effects of COVID-19 disease, and adverse effects of new treatments. Here we describe emerging evidence of the epidemiology of SARS-CoV-2 infection and underlying cardiovascular disease, the evidence for direct myocardial injury in SARS-CoV-2 infection, the specific presentations of cardiovascular involvement by SARS-CoV-2, and the cardiac effects of emerging treatments.

Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506. https://doi.org/10.1016/S0140-6736(20)30183-5.CrossRefPubMedPubMedCentral

COVID-19 Map. Johns Hopkins Coronavirus Resource Center. https://coronavirus.jhu.edu/map.html. Accessed 1 Jun 2020

Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054–62. https://doi.org/10.1016/S0140-6736(20)30566-3.CrossRefPubMedPubMedCentral

CDC. COVID-19 in Racial and Ethnic Minority Groups. Centers for disease control and prevention. Published Feb 11, 2020. https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/racial-ethnic-minorities.html. Accessed 1 Jun 2020

Peiris JSM, Lai ST, Poon LLM, et al. Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet. 2003;361(9366):1319–25. https://doi.org/10.1016/s0140-6736(03)13077-2.CrossRefPubMedPubMedCentral

Ksiazek TG, Erdman D, Goldsmith CS, et al. A novel coronavirus associated with severe acute respiratory syndrome. N Engl J Med. 2003;348(20):1953–66. https://doi.org/10.1056/NEJMoa030781.CrossRefPubMed

Drosten C, Günther S, Preiser W, et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med. 2003;348(20):1967–76. https://doi.org/10.1056/NEJMoa030747.CrossRefPubMed

Zaki AM, van Boheemen S, Bestebroer TM, Osterhaus ADME, Fouchier RAM. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med. 2012;367(19):1814–20. https://doi.org/10.1056/NEJMoa1211721.CrossRefPubMed

Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181(2):271–280.e8. https://doi.org/10.1016/j.cell.2020.02.052.CrossRefPubMedPubMedCentral

10.

Li W, Moore MJ, Vasilieva N, et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature. 2003;426(6965):450–4. https://doi.org/10.1038/nature02145.CrossRefPubMedPubMedCentral

11.

Imai Y, Kuba K, Rao S, et al. Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature. 2005;436(7047):112–6. https://doi.org/10.1038/nature03712.CrossRefPubMedPubMedCentral

12.

Kuba K, Imai Y, Rao S, et al. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nat Med. 2005;11(8):875–9. https://doi.org/10.1038/nm1267.CrossRefPubMedPubMedCentral

13.

Hamming I, Timens W, Bulthuis MLC, Lely AT, Navis GJ, van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol. 2004;203(2):631–7. https://doi.org/10.1002/path.1570.CrossRefPubMedPubMedCentral

14.

Crackower MA, Sarao R, Oudit GY, et al. Angiotensin-converting enzyme 2 is an essential regulator of heart function. Nature. 2002;417(6891):822–8. https://doi.org/10.1038/nature00786.CrossRefPubMed

15.

Chen L, Li X, Chen M, Feng Y, Xiong C. The ACE2 expression in human heart indicates new potential mechanism of heart injury among patients infected with SARS-CoV-2. Cardiovasc Res. 2020. https://doi.org/10.1093/cvr/cvaa078.CrossRefPubMedPubMedCentral

16.

COVID-19 situation reports. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports. Accessed 21 Apr 2020

17.

Guan W-J, Ni Z-Y, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382(18):1708–20. https://doi.org/10.1056/NEJMoa2002032.CrossRefPubMed

18.

Richardson S, Hirsch JS, Narasimhan M, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. JAMA. 2020. https://doi.org/10.1001/jama.2020.6775.CrossRefPubMedPubMedCentral

19.

Guo T, Fan Y, Chen M, et al. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020. https://doi.org/10.1001/jamacardio.2020.1017.CrossRefPubMedPubMedCentral

20.

Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan China. JAMA. 2020. https://doi.org/10.1001/jama.2020.1585.CrossRefPubMedPubMedCentral

21.

Shi S, Qin M, Shen B, et al. Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan China. JAMA Cardiol. 2020. https://doi.org/10.1001/jamacardio.2020.0950.CrossRefPubMedPubMedCentral

22.

Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72,314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020. https://doi.org/10.1001/jama.2020.2648.CrossRefPubMedPubMedCentral

23.

Garg S, Kim L, Whitaker M, et al. Hospitalization rates and characteristics of patients hospitalized with laboratory-confirmed coronavirus disease 2019—COVID-NET, 14 states, March 1–30, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(15):458–64. https://doi.org/10.15585/mmwr.mm6915e3.CrossRefPubMedPubMedCentral

24.

Goyal P, Choi JJ, Pinheiro LC, et al. Clinical characteristics of Covid-19 in New York City. N Engl J Med. 2020. https://doi.org/10.1056/NEJMc2010419.CrossRefPubMedPubMedCentral

25.

Thebault R, Tran AB, Williams V. The coronavirus is infecting and killing black Americans at an alarmingly high rate. Washington Post. https://www.washingtonpost.com/nation/2020/04/07/coronavirus-is-infecting-killing-black-americans-an-alarmingly-high-rate-post-analysis-shows/. Published 7 Apr 2020. Accessed 21 Apr 2020

26.

Haynes N, Cooper LA, Albert MA, Association of Black Cardiologists. At the heart of the matter: unmasking and addressing COVID-19’s toll on diverse populations. Circulation. 2020. https://doi.org/10.1161/CIRCULATIONAHA.120.048126.CrossRefPubMed

27.

Phelan JC, Link BG. Is racism a fundamental cause of inequalities in health? Ann Rev Sociol. 2015;41(1):311–30. https://doi.org/10.1146/annurev-soc-073014-112305.CrossRef

28.

Quinn SC, Kumar S, Freimuth VS, Musa D, Casteneda-Angarita N, Kidwell K. Racial disparities in exposure, susceptibility, and access to health care in the US H1N1 influenza pandemic. Am J Public Health. 2011;101(2):285–93. https://doi.org/10.2105/AJPH.2009.188029.CrossRefPubMedPubMedCentral

29.

Hadler JL, Yousey-Hindes K, Pérez A, et al. Influenza-related hospitalizations and poverty levels—United States, 2010–2012. MMWR Morb Mortal Wkly Rep. 2016;65(5):101–5. https://doi.org/10.15585/mmwr.mm6505a1.CrossRefPubMed

30.

Obermeyer Z, Powers B, Vogeli C, Mullainathan S. Dissecting racial bias in an algorithm used to manage the health of populations. Science. 2019;366(6464):447–53. https://doi.org/10.1126/science.aax2342.CrossRefPubMed

31.

Lippi G, Lavie CJ, Sanchis-Gomar F. Cardiac troponin I in patients with coronavirus disease 2019 (COVID-19): evidence from a meta-analysis. Prog Cardiovasc Dis. 2020. https://doi.org/10.1016/j.pcad.2020.03.001.CrossRefPubMedPubMedCentral

32.

Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. 2020. https://doi.org/10.1007/s00134-020-05991-x.CrossRefPubMedPubMedCentral

33.

Atri D, Siddiqi HK, Lang J, Nauffal V, Morrow DA, Bohula EA. COVID-19 for the cardiologist: a current review of the virology, clinical epidemiology, cardiac and other clinical manifestations and potential therapeutic strategies. JACC Basic Transl Sci. 2020. https://doi.org/10.1016/j.jacbts.2020.04.002.CrossRefPubMedPubMedCentral

34.

Hendren NS, Drazner MH, Bozkurt B, Cooper LT. Description and proposed management of the acute COVID-19 cardiovascular syndrome. Circulation. 2020. https://doi.org/10.1161/CIRCULATIONAHA.120.047349.CrossRefPubMedPubMedCentral

35.

Troponin and BNP Use in COVID-19. American College of Cardiology.https://www.acc.org/latest-in-cardiology/articles/2020/03/18/15/25/troponin-and-bnp-use-in-covid19. Accessed 21 Apr 2020

36.

Chapman AR, Bularga A, Mills NL. High-sensitivity cardiac troponin can be an ally in the fight against COVID-19. Circulation. 2020. https://doi.org/10.1161/CIRCULATIONAHA.120.047008.CrossRefPubMed

37.

Hu H, Ma F, Wei X, Fang Y. Coronavirus fulminant myocarditis treated with glucocorticoid and human immunoglobulin. Eur Heart J. 2020. https://doi.org/10.1093/eurheartj/ehaa190.CrossRefPubMedPubMedCentral

38.

Zeng J-H, Liu Y-X, Yuan J, et al. First case of COVID-19 complicated with fulminant myocarditis: a case report and insights. Infection. 2020. https://doi.org/10.1007/s15010-020-01424-5.CrossRefPubMedPubMedCentral

39.

Oudit GY, Kassiri Z, Jiang C, et al. SARS-coronavirus modulation of myocardial ACE2 expression and inflammation in patients with SARS. Eur J Clin Invest. 2009;39(7):618–25. https://doi.org/10.1111/j.1365-2362.2009.02153.x.CrossRefPubMedPubMedCentral

40.

Yu C, Wong RS, Wu EB, et al. Cardiovascular complications of severe acute respiratory syndrome. Postgrad Med J. 2006;82(964):140–4. https://doi.org/10.1136/pgmj.2005.037515.CrossRefPubMedPubMedCentral

41.

Alhogbani T. Acute myocarditis associated with novel Middle East Respiratory Syndrome coronavirus. Ann Saudi Med. 2016;36(1):78–80. https://doi.org/10.5144/0256-4947.2016.78.CrossRefPubMedPubMedCentral

42.

Inciardi RM, Lupi L, Zaccone G, et al. Cardiac involvement in a patient with coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020. https://doi.org/10.1001/jamacardio.2020.1096.CrossRefPubMedPubMedCentral

43.

Sala S, Peretto G, Gramegna M, et al. Acute myocarditis presenting as a reverse Tako-Tsubo syndrome in a patient with SARS-CoV-2 respiratory infection. Eur Heart J. 2020. https://doi.org/10.1093/eurheartj/ehaa286.CrossRefPubMed

44.

Tavazzi G, Pellegrini C, Maurelli M, et al. Myocardial localization of coronavirus in COVID-19 cardiogenic shock. Eur J Heart Fail. 2020. https://doi.org/10.1002/ejhf.1828.CrossRefPubMed

45.

Bhatraju PK, Ghassemieh BJ, Nichols M, et al. Covid-19 in critically ill patients in the Seattle region—case series. N Engl J Med. 2020. https://doi.org/10.1056/NEJMoa2004500.CrossRefPubMedPubMedCentral

46.

Kytömaa S, Hegde S, Claggett B, et al. Association of influenza-like illness activity with hospitalizations for heart failure: the Atherosclerosis Risk in Communities Study. JAMA Cardiol. 2019;4(4):363–9. https://doi.org/10.1001/jamacardio.2019.0549.CrossRefPubMedPubMedCentral

47.

Chen T, Wu D, Chen H, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019 retrospective study. BMJ. 2020;2020:368. https://doi.org/10.1136/bmj.m1091.CrossRef

48.

Extracorporeal Life Support Organization—ECMO and ECLS > Registry > Full COVID-19 Registry Dashboard. https://www.elso.org/Registry/FullCOVID19RegistryDashboard.aspx. Accessed 17 Apr 2020

49.

Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med. 2020;8(4):e21. https://doi.org/10.1016/S2213-2600(20)30116-8.CrossRefPubMedPubMedCentral

50.

Zhang P, Zhu L, Cai J, et al. Association of inpatient use of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers with mortality among patients with hypertension hospitalized with COVID-19. Circ Res. 2020. https://doi.org/10.1161/CIRCRESAHA.120.317134.CrossRefPubMedPubMedCentral

51.

Position Statement of the ESC Council on Hypertension on ACE-Inhibitors and Angiotensin Receptor Blockers. https://www.escardio.org/Councils/Council-on-Hypertension-(CHT)/News/position-statement-of-the-esc-council-on-hypertension-on-ace-inhibitors-and-ang, https://www.escardio.org/Councils/Council-on-Hypertension-(CHT)/News/position-statement-of-the-esc-council-on-hypertension-on-ace-inhibitors-and-ang. Accessed 17 Apr 2020

52.

HFSA/ACC/AHA Statement Addresses Concerns Re: Using RAAS Antagonists in COVID-19. American College of Cardiology. https://www.acc.org/latest-in-cardiology/articles/2020/03/17/08/59/hfsa-acc-aha-statement-addresses-concerns-re-using-raas-antagonists-in-covid-19. Accessed 17 Apr 2020

53.

Kwong JC, Schwartz KL, Campitelli MA, et al. Acute myocardial infarction after laboratory-confirmed influenza infection. N Engl J Med. 2018;378(4):345–53. https://doi.org/10.1056/NEJMoa1702090.CrossRefPubMed

54.

Jing Z-C, Zhu H-D, Yan X-W, Chai W-Z, Zhang S. Recommendations from the Peking Union Medical College Hospital for the management of acute myocardial infarction during the COVID-19 outbreak. Eur Heart J. 2020. https://doi.org/10.1093/eurheartj/ehaa258.CrossRefPubMed

55.

Welt FGP, Shah PB, Aronow HD, et al. Catheterization Laboratory considerations during the coronavirus (COVID-19) pandemic: from ACC’s Interventional Council and SCAI. J Am Coll Cardiol. 2020. https://doi.org/10.1016/j.jacc.2020.03.021.CrossRefPubMedPubMedCentral

56.

Mahmud E, Dauerman HL, Welt FG, et al. Management of acute myocardial infarction during the COVID-19 pandemic. J Am Coll Cardiol. 2020. https://doi.org/10.1016/j.jacc.2020.04.039.CrossRefPubMedPubMedCentral

57.

Bangalore S, Sharma A, Slotwiner A, et al. ST-segment elevation in patients with Covid-19—a case series. N Engl J Med. 2020. https://doi.org/10.1056/NEJMc2009020.CrossRefPubMedPubMedCentral

58.

Stefanini GG, Montorfano M, Trabattoni D, et al. ST-Elevation myocardial infarction in patients with COVID-19: clinical and angiographic outcomes. Circulation. 2020. https://doi.org/10.1161/CIRCULATIONAHA.120.047525.CrossRefPubMedPubMedCentral

59.

Garcia S, Albaghdadi MS, Meraj PM, et al. Reduction in ST-segment elevation cardiac catheterization laboratory activations in the United States during COVID-19 pandemic. J Am Coll Cardiol. 2020. https://doi.org/10.1016/j.jacc.2020.04.011.CrossRefPubMedPubMedCentral

60.

Rodríguez-Leor O, Alvarez-Álvarez B, Ojeda S, et al. Impacto de la pandemia de COVID-19 sobre la actividad asistencial en cardiología intervencionista en España. REC Interv Cardiol. 2020. https://doi.org/10.24875/RECIC.M20000120.CrossRef

61.

Tam C-CF, Cheung K-S, Lam S, et al. Impact of coronavirus disease 2019 (COVID-19) outbreak on ST-segment-elevation myocardial infarction care in Hong Kong, China. Circ Cardiovasc Qual Outcomes. 2020. https://doi.org/10.1161/CIRCOUTCOMES.120.006631.CrossRefPubMedPubMedCentral

62.

Klok FA, Kruip MJHA, van der Meer NJM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res. 2020. https://doi.org/10.1016/j.thromres.2020.04.013.CrossRefPubMedPubMedCentral

63.

Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost. 2020. https://doi.org/10.1111/jth.14817.CrossRefPubMedPubMedCentral

64.

Shao F, Xu S, Ma X, et al. In-hospital cardiac arrest outcomes among patients with COVID-19 pneumonia in Wuhan, China. Resuscitation. 2020. https://doi.org/10.1016/j.resuscitation.2020.04.005.CrossRefPubMedPubMedCentral

65.

Lazzerini PE, Laghi-Pasini F, Bertolozzi I, et al. Systemic inflammation as a novel QT-prolonging risk factor in patients with torsades de pointes. Heart. 2017;103(22):1821–9. https://doi.org/10.1136/heartjnl-2016-311079.CrossRefPubMed

66.

Lazzerini PE, Boutjdir M, Capecchi PL. COVID-19, arrhythmic risk and inflammation: mind the gap! Circulation. 2020. https://doi.org/10.1161/CIRCULATIONAHA.120.047293.CrossRefPubMed

67.

Kochi AN, Tagliari AP, Forleo GB, Fassini GM, Tondo C. Cardiac and arrhythmic complications in patients with COVID-19. J Cardiovasc Electrophysiol. 2020. https://doi.org/10.1111/jce.14479.CrossRefPubMedPubMedCentral

68.

Akhmerov A, Marban E. COVID-19 and the Heart. Circ Res. 2020. https://doi.org/10.1161/CIRCRESAHA.120.317055.CrossRefPubMed

69.

Omrani AS, Saad MM, Baig K, et al. Ribavirin and interferon alfa-2a for severe Middle East Respiratory Syndrome coronavirus infection: a retrospective cohort study. Lancet Infect Dis. 2014;14(11):1090–5. https://doi.org/10.1016/S1473-3099(14)70920-X.CrossRefPubMedPubMedCentral

70.

Driggin E, Madhavan MV, Bikdeli B, et al. Cardiovascular considerations for patients, health care workers, and health systems during the coronavirus disease 2019 (COVID-19) pandemic. J Am Coll Cardiol. 2020. https://doi.org/10.1016/j.jacc.2020.03.031.CrossRefPubMedPubMedCentral

71.

Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review. JAMA. 2020. https://doi.org/10.1001/jama.2020.6019.CrossRefPubMedPubMedCentral

72.

Tang W, Cao Z, Han M, et al. Hydroxychloroquine in patients with COVID-19: an open-label, randomized, controlled trial. medRxiv. 2020. https://doi.org/10.1101/2020.04.10.20060558.CrossRefPubMedPubMedCentral

73.

Colson P, Rolain J-M, Lagier J-C, Brouqui P, Raoult D. Chloroquine and hydroxychloroquine as available weapons to fight COVID-19. Int J Antimicrob Agents. 2020. https://doi.org/10.1016/j.ijantimicag.2020.105932.CrossRefPubMedPubMedCentral

74.

Bosseboeuf E, Aubry M, Nhan T, et al. Azithromycin inhibits the replication of zika virus. J Anti Antiretrovir. 2020. https://doi.org/10.4172/1948-5964.1000173.CrossRef

75.

Page RL, O’Bryant CL, Cheng D, et al. Drugs that may cause or exacerbate heart failure: a scientific statement from the American Heart Association. Circulation. 2016;134(6):e32–69. https://doi.org/10.1161/CIR.0000000000000426.CrossRefPubMed

76.

Tönnesmann E, Kandolf R, Lewalter T. Chloroquine cardiomyopathy—a review of the literature. Immunopharmacol Immunotoxicol. 2013;35(3):434–42. https://doi.org/10.3109/08923973.2013.780078.CrossRefPubMed

77.

Cao B, Wang Y, Wen D, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. N Engl J Med. 2020. https://doi.org/10.1056/NEJMoa2001282.CrossRefPubMedPubMedCentral

78.

KALETRA® oral film coated tablets, oral solution, lopinavir ritonavir oral film coated tablets, oral solution. Product Insert

79.

Siegel D, Hui HC, Doerffler E, et al. Discovery and synthesis of a phosphoramidate prodrug of a pyrrolo[2,1-f][triazin-4-amino] adenine C-nucleoside (GS-5734) for the treatment of Ebola and emerging viruses. J Med Chem. 2017;60(5):1648–61. https://doi.org/10.1021/acs.jmedchem.6b01594.CrossRefPubMedPubMedCentral

80.

Mulangu S, Dodd LE, Davey RT, et al. A randomized, controlled trial of Ebola virus disease therapeutics. N Engl J Med. 2019;381(24):2293–303. https://doi.org/10.1056/NEJMoa1910993.CrossRefPubMed

81.

Meduri GU, Golden E, Freire AX, et al. Methylprednisolone infusion in early severe ARDS: results of a randomized controlled trial. Chest. 2007;131(4):954–63. https://doi.org/10.1378/chest.06-2100.CrossRefPubMed

82.

Fang X, Mei Q, Yang T, et al. Low-dose corticosteroid therapy does not delay viral clearance in patients with COVID-19. J Infect. 2020. https://doi.org/10.1016/j.jinf.2020.03.039.CrossRefPubMedPubMedCentral

83.

Yang Z, Liu J, Zhou Y, Zhao X, Zhao Q, Liu J. The effect of corticosteroid treatment on patients with coronavirus infection: a systematic review and meta-analysis. J Infect. 2020. https://doi.org/10.1016/j.jinf.2020.03.062.CrossRefPubMedPubMedCentral

84.

Xu X, Han M, Li T, et al.(2020) Effective treatment of severe COVID-19 patients with tocilizumab 12

85.

Shen C, Wang Z, Zhao F, et al. Treatment of 5 critically ill patients with COVID-19 with convalescent plasma. JAMA. 2020. https://doi.org/10.1001/jama.2020.4783.CrossRefPubMedPubMedCentral

Title: Cardiovascular Implications and Therapeutic Considerations in COVID-19 Infection
Authors: Gregory L. Judson
Benjamin W. Kelemen
Joyce N. Njoroge
Vaikom S. Mahadevan
Publication date: 01-12-2020
Publisher: Springer Healthcare
Keywords: Coronavirus
Myocarditis
SARS-CoV-2
COVID-19
Published in: Cardiology and Therapy / Issue 2/2020
Print ISSN: 2193-8261
Electronic ISSN: 2193-6544
DOI: https://doi.org/10.1007/s40119-020-00184-5

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2020

Lipoprotein(a) and Cardiovascular Disease Prevention across Diverse Populations

In-Hospital Outcomes of Patients with Acute Decompensated Heart Failure and Cirrhosis: An Analysis of the National Inpatient Sample

Optical Coherence Tomography: Current Applications for the Assessment of Coronary Artery Disease and Guidance of Percutaneous Coronary Interventions

A Phase 4, Open-Label, Single-Arm Study Assessing the Efficacy and Safety of Ivabradine in African American Patients with Heart Failure and Reduced Ejection Fraction

Extrapolation of Survival Benefits in Patients with Transthyretin Amyloid Cardiomyopathy Receiving Tafamidis: Analysis of the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial

Safety and Effectiveness of Hydroxychloroquine and Azithromycin Combination Therapy for Treatment of Hospitalized Patients with COVID-19: A Propensity-Matched Study

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage